Factor VIII inhibitors in patients with hemophilia A

Oren H., Yaprak I., Irken G.

ACTA HAEMATOLOGICA, cilt.102, sa.1, ss.42-46, 1999 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 102 Sayı: 1
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1159/000040966
  • Dergi Adı: ACTA HAEMATOLOGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.42-46
  • Anahtar Kelimeler: factor VIII, hemophilia A, inhibitors, PREVIOUSLY UNTREATED PATIENTS, RECOMBINANT FACTOR-VIII, PURITY FACTOR-VIII, A PATIENTS, MULTITRANSFUSED HEMOPHILIA, IMMUNE TOLERANCE, NATURAL-HISTORY, CONCENTRATE, SAFETY, MANAGEMENT
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

In 58 hemophilia A patients aged 1-18 years (mean 9.5 +/- 4.7 years), the prevalence-of inhibitors was found to be 27% by the Bethesda method in November 1995. Inhibitor activity was not detected in any of 14 patients with mild hemophilia while it was present in 9 of 27 (33%) patients with moderate, and 7 of 17 (41%) with severe disease, During follow-up, the inhibitors were transient in 10 of 16 patients (17%) and the prevalence of inhibitors was 10% at the end of the study. Our study has demonstrated that the patients' age, factor VIII (F VIII) coagulant activity levels, type of F VIII replacement therapy, and frequency of F VIII administration affect inhibitor development, and these factors should be considered in the follow-up of hemophiliacs.